Niranjan Y Sardesai

List of Publications by Year
in descending order

122 papers	5,985 citations	71102 41 h-index	85541 71 g-index
124 all docs	124 docs citations	124 times ranked	6616 citing authors

#	Article	IF	Citations
1	Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet, The, 2015, 386, 2078-2088.	13.7	529
2	Electroporation delivery of DNA vaccines: prospects for success. Current Opinion in Immunology, 2011, 23, 421-429.	5.5	354
3	Immunotherapy Against HPV16/18 Generates Potent T _H 1 and Cytotoxic Cellular Immune Responses. Science Translational Medicine, 2012, 4, 155ra138.	12.4	260
4	A synthetic consensus antiâ€“spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Science Translational Medicine, 2015, 7, 301ra132.	12.4	214
5	Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery. Journal of Infectious Diseases, 2013, 208, 818-829.	4.0	171
6	Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine, 2008, 26, 5128-5134.	3.8	156
7	A DNA Vaccine against Chikungunya Virus Is Protective in Mice and Induces Neutralizing Antibodies in Mice and Nonhuman Primates. PLoS Neglected Tropical Diseases, 2011, 5, e928.	3.0	155
8	MESOMARKâ„¢: A Potential Test for Malignant Pleural Mesothelioma. Clinical Chemistry, 2007, 53, 666-672.	3.2	127
9	Heterosubtypic Protection against Pathogenic Human and Avian Influenza Viruses via In Vivo Electroporation of Synthetic Consensus DNA Antigens. PLoS ONE, 2008, 3, e2517.	2.5	124
10	In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. Npj Vaccines, 2016, 1, 16021.	6.0	118
11	Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic Marker. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1014-1020.	2.5	100
12	Intradermal SynConÂ® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers. Journal of Infectious Diseases, 2019, 220, 400-410.	4.0	91
13	DNA vaccination protects mice against Zika virus-induced damage to the testes. Nature Communications, 2017, 8, 15743.	12.8	90
14	Activated CD4 ⁺ CCR5 ⁺ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 518-523.	7.1	88
15	A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. Journal of Translational Medicine, 2015, 13, 60.	4.4	84
16	DNA Recognition by Peptide Complexes of Rhodium(III): Example of a Glutamate Switch. Journal of the American Chemical Society, 1994, 116, 7502-7508.	13.7	79
17	Multivalent Smallpox DNA Vaccine Delivered by Intradermal Electroporation Drives Protective Immunity in Nonhuman Primates Against Lethal Monkeypox Challenge. Journal of Infectious Diseases, 2011, 203, 95-102.	4.0	78
18	Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus. Journal of Infectious Diseases, 2016, 214, 369-378.	4.0	77

#	Article	IF	Citations
19	Tolerability of intramuscular and intradermal delivery by CELLECTRA^{Â®}adaptive constant current electroporation device in healthy volunteers. Human Vaccines and Immunotherapeutics, 2013, 9, 2246-2252.	3.3	75
20	A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor Challenge. Cancer Immunology Research, 2019, 7, 174-182.	3.4	75
21	DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2975-2980.	7.1	71
22	The p40 Subunit of Interleukin (IL)-12 Promotes Stabilization and Export of the p35 Subunit. Journal of Biological Chemistry, 2013, 288, 6763-6776.	3.4	70
23	IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques. Human Vaccines and Immunotherapeutics, 2012, 8, 1620-1629.	3.3	67
24	Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy. Scientific Reports, 2015, 5, 12616.	3.3	65
25	Enhanced Control of Pathogenic Simian Immunodeficiency Virus SIVmac239 Replication in Macaques Immunized with an Interleukin-12 Plasmid and a DNA Prime-Viral Vector Boost Vaccine Regimen. Journal of Virology, 2011, 85, 9578-9587.	3.4	63
26	Therapeutic DNA Vaccination Using In Vivo Electroporation Followed by Standard of Care Therapy in Patients With Genotype 1 Chronic Hepatitis C. Molecular Therapy, 2013, 21, 1796-1805.	8.2	62
27	A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. Human Vaccines and Immunotherapeutics, 2017, 13, 2902-2911.	3.3	61
28	Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device. Gene Therapy, 2011, 18, 258-265.	4.5	60
29	IL-28B/IFN-Î»3 Drives Granzyme B Loading and Significantly Increases CTL Killing Activity in Macaques. Molecular Therapy, 2010, 18, 1714-1723.	8.2	53
30	Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer. Expert Review of Vaccines, 2013, 12, 271-283.	4.4	52
31	A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine, 2011, 29, 6771-6780.	3.8	48
32	Highly Optimized DNA Vaccine Targeting Human Telomerase Reverse Transcriptase Stimulates Potent Antitumor Immunity. Cancer Immunology Research, 2013, 1, 179-189.	3.4	48
33	Altered Response Hierarchy and Increased T-Cell Breadth upon HIV-1 Conserved Element DNA Vaccination in Macaques. PLoS ONE, 2014, 9, e86254.	2.5	47
34	Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation. Vaccines, 2013, 1, 262-277.	4.4	46
35	An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model. Nature Communications, 2017, 8, 637.	12.8	45
36	Optimization of Electroporation-Enhanced Intradermal Delivery of DNA Vaccine Using a Minimally Invasive Surface Device. Human Gene Therapy Methods, 2012, 23, 157-168.	2.1	44

#	Article	IF	Citations
37	Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ. Vaccines, 2013, 1, 367-383.	4.4	44
38	Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation Device. Human Gene Therapy Methods, 2015, 26, 134-146.	2.1	44
39	HIV-1 p24gag Derived Conserved Element DNA Vaccine Increases the Breadth of Immune Response in Mice. PLoS ONE, 2013, 8, e60245.	2.5	44
40	Construction of Coordinatively Saturated Rhodium Complexes Containing Appended Peptides. Bioconjugate Chemistry, 1995, 6, 302-312.	3.6	43
41	Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques. Molecular Therapy, 2010, 18, 1568-1576.	8.2	42
42	Inducing Humoral and Cellular Responses to Multiple Sporozoite and Liver-Stage Malaria Antigens Using Exogenous Plasmid DNA. Infection and Immunity, 2013, 81, 3709-3720.	2.2	42
43	A Heterologous Prime/Boost Vaccination Strategy Enhances the Immunogenicity of Therapeutic Vaccines for Hepatitis C Virus. Journal of Infectious Diseases, 2013, 208, 1008-1019.	4.0	42
44	DNA and Protein Co-Immunization Improves the Magnitude and Longevity of Humoral Immune Responses in Macaques. PLoS ONE, 2014, 9, e91550.	2.5	42
45	DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections. Npj Vaccines, 2017, 2, 18.	6.0	42
46	Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII. Vaccine, 2009, 27, 4370-4380.	3.8	41
47	Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine. Vaccine, 2014, 32, 2833-2842.	3.8	41
48	Development of a novel DNA SynConâ„¢ tetravalent dengue vaccine that elicits immune responses against four serotypes. Vaccine, 2009, 27, 6444-6453.	3.8	40
49	Control of Heterologous Simian Immunodeficiency Virus SIV _{smE660} Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. Journal of Virology, 2018, 92, .	3.4	39
50	Unique Th1/Th2 Phenotypes Induced during Priming and Memory Phases by Use of Interleukin-12 (IL-12) or IL-28B Vaccine Adjuvants in Rhesus Macaques. Vaccine Journal, 2010, 17, 1493-1499.	3.1	38
51	InÂVivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model. Cell Reports, 2018, 25, 1982-1993.e4.	6.4	38
52	Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine. Vaccine, 2011, 29, 7173-7181.	3.8	37
53	<scp>VGX</scp>â€1027 modulates genes involved in lipopolysaccharideâ€induced <scp>T</scp>ollâ€like receptor 4 activation and in a murine model of systemic lupus erythematosus. Immunology, 2014, 142, 594-602.	4.4	37
54	Hepatitis C Virus NS3/NS4A DNA Vaccine Induces Multiepitope T Cell Responses in Rhesus Macaques Mimicking Human Immune Responses. Molecular Therapy, 2012, 20, 669-678.	8.2	36

#	Article	IF	Citations
55	Detection of Newly Diagnosed Bladder Cancer, Bladder Cancer Recurrence and Bladder Cancer in Patients with Hematuria Using Quantitative RT-PCR of Urinary Survivin. Tumor Biology, 2007, 28, 57-62.	1.8	35
56	High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation. Vaccine, 2011, 29, 6763-6770.	3.8	35
57	DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV. Journal of Immunology, 2016, 197, 3999-4013.	0.8	33
58	Chemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challenge. Mucosal Immunology, 2016, 9, 13-23.	6.0	33
59	DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques. Cancer Gene Therapy, 2013, 20, 652-662.	4.6	32
60	Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy. Clinical Cancer Research, 2018, 24, 276-294.	7.0	32
61	Intradermal DNA Vaccination Enhanced by Low-Current Electroporation Improves Antigen Expression and Induces Robust Cellular and Humoral Immune Responses. Human Gene Therapy, 2012, 23, 943-950.	2.7	31
62	Electroporation mediated DNA vaccination directly to a mucosal surface results in improved immune responses. Human Vaccines and Immunotherapeutics, 2013, 9, 2041-2048.	3.3	31
63	An Optimized, Synthetic DNA Vaccine Encoding the Toxin A and Toxin B Receptor Binding Domains of Clostridium difficile Induces Protective Antibody ResponsesIn Vivo. Infection and Immunity, 2014, 82, 4080-4091.	2.2	31
64	Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody. Cancer Immunology, Immunotherapy, 2017, 66, 1577-1588.	4.2	31
65	Optimized In Vivo Transfer of Small Interfering RNA Targeting Dermal Tissue Using In Vivo Surface Electroporation. Molecular Therapy - Nucleic Acids, 2012, 1, e11.	5.1	30
66	Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100. Molecular Therapy - Oncolytics, 2016, 3, 16025.	4.4	30
67	Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines. Journal of Infectious Diseases, 2019, 219, 544-555.	4.0	30
68	Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses. Hum Vaccin, 2011, 7, 120-127.	2.4	29
69	HIV-1 Env DNA Vaccine plus Protein Boost Delivered by EP Expands B- and T-Cell Responses and Neutralizing Phenotype In Vivo. PLoS ONE, 2013, 8, e84234.	2.5	29
70	A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity. Molecular Therapy, 2017, 25, 976-988.	8.2	29
71	Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques. Vaccine, 2011, 29, 6742-6754.	3.8	28
72	A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge. Vaccine, 2011, 29, 6755-6762.	3.8	27

#	Article	IF	Citations
73	Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model. Cancer Gene Therapy, 2014, 21, 507-517.	4.6	27
74	Novel synthetic plasmid and Doggyboneâ„¢ DNA vaccines induce neutralizing antibodies and provide protection from lethal influenza challenge in mice. Human Vaccines and Immunotherapeutics, 2015, 11, 1972-1982.	3.3	27
75	Influenza A vaccines using linear expression cassettes delivered via electroporation afford full protection against challenge in a mouse model. Vaccine, 2012, 30, 6946-6954.	3.8	26
76	Nonstructural Protein 2 (nsP2) of Chikungunya Virus (CHIKV) Enhances Protective Immunity Mediated by a CHIKV Envelope Protein Expressing DNA Vaccine. Viral Immunology, 2013, 26, 75-83.	1.3	26
77	Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques. Human Vaccines and Immunotherapeutics, 2013, 9, 2081-2094.	3.3	26
78	Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus. Vaccine, 2017, 35, 2840-2847.	3.8	26
79	Robust antibody and cellular responses induced by DNA-only vaccination for HIV. JCI Insight, 2020, 5, .	5.0	25
80	Long-Term Programming of Antigen-Specific Immunity from Gene Expression Signatures in the PBMC of Rhesus Macaques Immunized with an SIV DNA Vaccine. PLoS ONE, 2011, 6, e19681.	2.5	25
81	Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Human Vaccines and Immunotherapeutics, 2014, 10, 2357-2365.	3.3	24
82	Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques. Clinical Immunology, 2014, 155, 91-107.	3.2	24
83	Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost. Journal of Infectious Diseases, 2017, 216, 1080-1090.	4.0	23
84	DNA vaccination strategy targets epidermal dendritic cells, initiating their migration and induction of a host immune response. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14054.	4.1	22
85	DNA recognition by metal-peptide complexes containing the recognition helix of the phage 434 repressor. Journal of Biological Inorganic Chemistry, 1997, 2, 762-771.	2.6	21
86	Efficient 50S Ribosome-Catalyzed Peptide Bond Synthesis with an Aminoacyl Minihelixâ€. Biochemistry, 1999, 38, 12080-12088.	2.5	21
87	Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice. Human Vaccines and Immunotherapeutics, 2012, 8, 1668-1681.	3.3	21
88	Functional analysis of peptide motif for RNA microhelix binding suggests new family of RNA-binding domains. EMBO Journal, 1998, 17, 5449-5457.	7.8	20
89	Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses. Clinical Immunology, 2014, 153, 308-322.	3.2	20
90	Synthetic Consensus HIV-1 DNA Induces Potent Cellular Immune Responses and Synthesis of Granzyme B, Perforin in HIV Infected Individuals. Molecular Therapy, 2015, 23, 591-601.	8.2	19

#	Article	IF	Citations
91	Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine. Vaccine, 2018, 36, 3079-3089.	3.8	18
92	Piezoelectric permeabilization of mammalian dermal tissue for in vivo DNA delivery leads to enhanced protein expression and increased immunogenicity. Hum Vaccin, 2011, 7, 22-28.	2.4	17
93	Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen. Human Vaccines and Immunotherapeutics, 2012, 8, 470-478.	3.3	17
94	An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge. Vaccine, 2012, 30, 3202-3208.	3.8	17
95	HIV Env conserved element DNA vaccine alters immunodominance in macaques. Human Vaccines and Immunotherapeutics, 2017, 13, 2859-2871.	3.3	17
96	DNA Vaccination in Skin Enhanced by Electroporation. Methods in Molecular Biology, 2014, 1143, 123-130.	0.9	16
97	A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin. Human Vaccines and Immunotherapeutics, 2015, 11, 746-754.	3.3	15
98	In vitro inhibition of enterobacteria-reactive CD4+CD25â˜ T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. European Journal of Pharmacology, 2008, 586, 313-321.	3.5	14
99	An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates. Journal of Virology, 2015, 89, 9154-9166.	3.4	14
100	Gag and env conserved element CE DNA vaccines elicit broad cytotoxic T cell responses targeting subdominant epitopes of HIV and SIV Able to recognize virus-infected cells in macaques. Human Vaccines and Immunotherapeutics, 2018, 14, 2163-2177.	3.3	14
101	Clinical Development of Intramuscular Electroporation: Providing a â€œBoostâ€•for DNA Vaccines. Methods in Molecular Biology, 2014, 1121, 279-289.	0.9	14
102	Immunogenicity of a novel enhanced consensus DNA vaccine encoding the leptospiral protein LipL45. Human Vaccines and Immunotherapeutics, 2015, 11, 1945-1953.	3.3	12
103	Safety, bioavailability, and pharmacokinetics of VGXâ€1027â€”A novel oral antiâ€inflammatory drug in healthy human subjects. Clinical Pharmacology in Drug Development, 2016, 5, 91-101.	1.6	12
104	DNA Vaccineâ€“Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination. Human Gene Therapy, 2018, 29, 1029-1043.	2.7	12
105	Elucidating the Kinetics of Expression and Immune Cell Infiltration Resulting from Plasmid Gene Delivery Enhanced by Surface Dermal Electroporation. Vaccines, 2013, 1, 384-397.	4.4	11
106	Dose-dependent inhibition of Gag cellular immunity by Env in SIV/HIV DNA vaccinated macaques. Human Vaccines and Immunotherapeutics, 2015, 11, 2005-2011.	3.3	11
107	Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization. Journal of Infectious Diseases, 2019, 219, 365-374.	4.0	11
108	Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GPÂ® DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults. Vaccines, 2020, 8, 741.	4.4	11

#	Article	IF	Citations
109	Direct Transfection of Dendritic Cells in the Epidermis After Plasmid Delivery Enhanced by Surface Electroporation. Human Gene Therapy Methods, 2014, 25, 315-316.	2.1	10
110	Recombinant rubella vectors elicit SIV Gag-specific T cell responses with cytotoxic potential in rhesus macaques. Vaccine, 2015, 33, 2167-2174.	3.8	9
111	Analysis of the Potential for HIV-1 Vpr as an Anti-Cancer Agent. Current HIV Research, 2009, 7, 144-152.	0.5	7
112	Introduction to DNA vaccines â€“ Las Vegas. Vaccine, 2010, 28, 1893-1896.	3.8	7
113	Plasmodium inui Infection Reduces the Efficacy of a Simian Immunodeficiency Virus DNA Vaccine in a Rhesus Macaque Model Through Alteration of the Vaccine-Induced Immune Response. Journal of Infectious Diseases, 2012, 206, 523-33.	4.0	7
114	DNA vaccines targeting heavy chain C-terminal fragments ofClostridium botulinumneurotoxin serotypes A, B, and E induce potent humoral and cellular immunity and provide protection from lethal toxin challenge. Human Vaccines and Immunotherapeutics, 2015, 11, 1961-1971.	3.3	7
115	A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust TÂcell generation. Molecular Therapy - Oncolytics, 2021, 21, 278-287.	4.4	7
116	Noncovalent Assembly of Microhelix Recognition by a Class II tRNA Synthetase. Journal of the American Chemical Society, 1998, 120, 3269-3270.	13.7	6
117	A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin. Human Vaccines and Immunotherapeutics, 2014, 10, 3039-3047.	3.3	5
118	DNA-based influenza vaccines: evaluating their potential to provide universal protection. IDrugs: the Investigational Drugs Journal, 2010, 13, 707-12.	0.7	4
119	Protocols for Developing Novel Chikungunya Virus DNA Vaccines. Methods in Molecular Biology, 2016, 1426, 311-332.	0.9	2
120	RNA Scaffolds for Minihelix-Based Aminoacyl Transfer: Design of â€œTranspeptizymesâ€• Journal of Biomolecular Structure and Dynamics, 2000, 17, 29-37.	3.5	1
121	DNA vaccines 2010: A gumbo of accomplishment and excitement in New Orleans. Vaccine, 2011, 29, 6721-6722.	3.8	0
122	Adventures of a vaccinologist entrepreneur. Human Vaccines and Immunotherapeutics, 2014, 10, 1431-1435.	3.3	0